{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:14:38Z","timestamp":1775121278804,"version":"3.50.1"},"reference-count":208,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene targeted therapy for spinal muscular atrophy (SMA) has laid the foundation for developing highly personalized therapies for other neurodegenerative disorders. As intensive research and efforts to advance gene targeted therapies continue, this review provides an overview of viral and non-viral vectors and delivery methods, as well as treatment strategies, including gene addition, replacement, editing, silencing, and splice modulation. Gene targeted approaches and clinical trials for SMA and amyotrophic lateral sclerosis (ALS) have demonstrated success, and additional studies are in progress. The design of efficient clinical trials which facilitate successful translation into clinical practice is of critical importance. Key considerations include the selection of appropriate disease models, understanding the natural history of the disease, and establishing well-defined outcome measures to assess prognosis of the disease and therapeutic efficacy. Finally, the precision of CRISPR-based gene editing offers the potential for one-time corrective therapies for monogenic disorders like SMA and SOD1-ALS.<\/jats:p>","DOI":"10.3390\/genes17040419","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:57:55Z","timestamp":1775116675000},"page":"419","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-4088","authenticated-orcid":false,"given":"Ayse","family":"Yesbek Kaymaz","sequence":"first","affiliation":[{"name":"National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Dr., Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamze","family":"Bora-Ako\u011flu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Biology, Hacettepe University, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayat","family":"Erdem Yurter","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Biology, Hacettepe University, 06100 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Grunseich","sequence":"additional","affiliation":[{"name":"National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Dr., Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113324","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_2","unstructured":"U.S. Food and Drug Administration (FDA) (2025, October 27). What Is Gene Therapy?, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/what-gene-therapy."},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2025, June 01). International Clinical Trials Registry Platform (ICTRP). Available online: https:\/\/trialsearch.who.int\/Default.aspx."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107502","DOI":"10.1016\/j.biotechadv.2019.107502","article-title":"The approved gene therapy drugs worldwide: From 1998 to 2019","volume":"40","author":"Ma","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (FDA) (2026, March 18). Purple Book Database, Available online: https:\/\/purplebooksearch.fda.gov\/."},{"key":"ref_6","unstructured":"(2026, March 18). European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"ref_7","first-page":"249","article-title":"Gene therapy, early promises, subsequent problems, and recent breakthroughs","volume":"3","author":"Baradaran","year":"2013","journal-title":"Adv. Pharm. Bull."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/mt.2009.41","article-title":"Biological gene delivery vehicles: Beyond viral vectors","volume":"17","author":"Seow","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.drudis.2021.03.021","article-title":"The era of gene therapy: From preclinical development to clinical application","volume":"26","author":"Alhakamy","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shin, M.H., He, Y., Marrogi, E., Piperdi, S., Ren, L., Khanna, C., Gorlick, R., Liu, C., and Huang, J. (2016). A RUNX2-mediated epigenetic regulation of the survival of p53 defective cancer cells. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1005884"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1073\/pnas.1520244113","article-title":"Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: Last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Nowrouzi","year":"2008","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik\u2019s cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Song","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","article-title":"Intracellular trafficking of adeno-associated virus (AAV) vectors: Challenges and future directions","volume":"28","author":"Riyad","year":"2021","journal-title":"Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: Fulfilling the promise of therapeutic genome editing","volume":"38","author":"Li","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cichon, M., Jozkowicz, A., and Grochot-Przeczek, A. (2026). Advances in Endothelial Cell Targeting by AAV Vectors. Acta Biochim. Pol., 73.","DOI":"10.3389\/abp.2026.15740"},{"key":"ref_25","first-page":"GE01","article-title":"Non viral vectors in gene therapy\u2014An overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41587-019-0402-x","article-title":"Emerging patent landscape for non-viral vectors used for gene therapy","volume":"38","author":"Pereira","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2100040","DOI":"10.1002\/adtp.202100040","article-title":"Engineering gene therapy: Advances and barriers","volume":"4","author":"Shahryari","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_28","first-page":"409","article-title":"MSC based gene delivery methods and strategies improve the therapeutic efficacy of neurological diseases","volume":"23","author":"Zhou","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: Recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.molmed.2025.01.015","article-title":"Gene Therapies for Neurogenetic Disorders","volume":"31","author":"Devinsky","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41582-022-00751-5","article-title":"Prospects for gene replacement therapies in amyotrophic lateral sclerosis","volume":"19","author":"Giovannelli","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., and Betapudi, V. (2019). Gene therapy leaves a vicious cycle. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00297"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Poletto, E., Baldo, G., and Gomez-Ospina, N. (2020). Genome editing for mucopolysaccharidoses. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020500"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-based therapies for neurodegenerative diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","article-title":"Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements","volume":"60","author":"Mojica","year":"2005","journal-title":"J. Mol. Evol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: A decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/crispr.2020.0064","article-title":"CRISPR-Cas activators for engineering gene expression in higher eukaryotes","volume":"3","author":"Zinselmeier","year":"2020","journal-title":"CRISPR J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"dmm039982","DOI":"10.1242\/dmm.039982","article-title":"CRISPR\/Cas9-mediated genome editing in nonhuman primates","volume":"12","author":"Kang","year":"2019","journal-title":"Dis. Model Mech."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","article-title":"In vivo somatic cell base editing and prime editing","volume":"29","author":"Newby","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41586-025-09537-3","article-title":"Engineered prime editors with minimal genomic errors","volume":"646","author":"Chauhan","year":"2025","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s12276-025-01463-8","article-title":"Emerging trends in prime editing for precision genome editing","volume":"57","author":"Lee","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yashooa, R.K., Nabi, A.Q., Smail, S.W., Azeez, S.S., Nooh, W.A., Mustafa, S.A., Al-Farha, A.A.-B., Capitanio, N., and Shekha, M.S. (2026). CRISPR\u2013Cas technologies in neurodegenerative disorders: Mechanistic insights, therapeutic potential, and translational challenges. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1737468"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.tibtech.2023.03.004","article-title":"Prime editing: Advances and therapeutic applications","volume":"41","author":"Zhao","year":"2023","journal-title":"Trends Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: Translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"177644","DOI":"10.1016\/j.ejphar.2025.177644","article-title":"Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatment","volume":"999","author":"Dudzisz","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.omtn.2017.07.006","article-title":"Gapmer antisense oligonucleotides suppress the mutant allele of COL6A3 and restore functional protein in Ullrich muscular dystrophy","volume":"8","author":"Marrosu","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/nar\/gkw065","article-title":"RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery","volume":"44","author":"Lima","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene therapy for ALS: A review","volume":"29","author":"Amado","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/hum.2024.113","article-title":"Advances in microRNA therapeutics: From preclinical to clinical studies","volume":"35","author":"Brillante","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mt.2013.285","article-title":"Recombinant AAV as a platform for translating the therapeutic potential of RNA interference","volume":"22","author":"Borel","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e186116","DOI":"10.1172\/JCI186116","article-title":"The expanding application of antisense oligonucleotides to neurodegenerative diseases","volume":"134","author":"Sumner","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"104010","DOI":"10.1016\/j.mcn.2025.104010","article-title":"RNA-Based Therapies for Neurodegenerative Disease: Targeting Molecular Mechanisms for Disease Modification","volume":"133","author":"Bhati","year":"2025","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800148-6.00004-3","article-title":"Lipid nanoparticles for short interfering RNA delivery","volume":"88","author":"Leung","year":"2014","journal-title":"Adv. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-800148-6.00003-1","article-title":"Nanotechnology for in vivo targeted siRNA delivery","volume":"88","author":"Dahlman","year":"2014","journal-title":"Adv. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/nar\/gkae141","article-title":"Chemical modification patterns for microRNA therapeutic mimics: A structure-activity relationship (SAR) case-study on miR-200c","volume":"52","author":"Garreau","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.62642","article-title":"Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhang, X. (2024). Splice-Switching Antisense Oligonucleotides for Pediatric Neurological Disorders. Front. Mol. Neurosci., 17.","DOI":"10.3389\/fnmol.2024.1412964"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"McDowall, S., Aung-Htut, M., Wilton, S., and Li, D. (2024). Antisense Oligonucleotides and Their Applications in Rare Neurological Diseases. Front. Neurosci., 18.","DOI":"10.3389\/fnins.2024.1414658"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","article-title":"Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases","volume":"38","author":"Chen","year":"2024","journal-title":"BioDrugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: The next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: In the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","article-title":"Challenges and opportunities in spinal muscular atrophy therapeutics","volume":"23","author":"Yeo","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: Mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1093\/hmg\/ddq329","article-title":"Cardiac defects contribute to the pathology of spinal muscular atrophy models","volume":"19","author":"Shababi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/hmg\/ddaa126","article-title":"Renal pathology in a mouse model of severe spinal muscular atrophy is associated with downregulation of glial cell-line derived neurotrophic factor (GDNF)","volume":"29","author":"Allardyce","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ana.24549","article-title":"Vascular defects and spinal cord hypoxia in spinal muscular atrophy","volume":"79","author":"Somers","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1073858417705059","article-title":"The actin cytoskeleton in SMA and ALS: How does it contribute to motoneuron degeneration?","volume":"24","author":"Hensel","year":"2018","journal-title":"Neuroscientist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mus.27715","article-title":"Alterations in insulin-like growth factor system in spinal muscular atrophy","volume":"66","author":"Kaymaz","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1093\/hmg\/ddaa275","article-title":"Microtubule-associated protein 1B dysregulates microtubule dynamics and neuronal mitochondrial transport in spinal muscular atrophy","volume":"29","author":"Bora","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/brain\/awae272","article-title":"The systemic complexity of a monogenic disease: The molecular network of spinal muscular atrophy","volume":"148","author":"Tapken","year":"2025","journal-title":"Brain"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"103725","DOI":"10.1016\/j.mcn.2022.103725","article-title":"SMN loss dysregulates microtubule-associated proteins in spinal muscular atrophy model","volume":"120","author":"Son","year":"2022","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1747-0285.2009.00781.x","article-title":"Histone deacetylase inhibition activity and molecular docking of (E)-resveratrol: Its therapeutic potential in spinal muscular atrophy","volume":"73","author":"Bora","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","article-title":"Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy\u2014Insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","article-title":"Therapy development for spinal muscular atrophy: Perspectives for muscular dystrophies and neurodegenerative disorders","volume":"4","author":"Jablonka","year":"2022","journal-title":"Neurol. Res. Pract."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"ref_96","unstructured":"Biogen (2025, May 13). SPINRAZA\u00ae (Nusinersen). Available online: https:\/\/www.spinraza.com\/."},{"key":"ref_97","unstructured":"(2025, May 14). Novartis Gene Therapies. ZOLGENSMA\u00ae (Onasemnogene Abeparvovec-Xioi). Available online: https:\/\/www.zolgensma.com\/."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_99","unstructured":"(2025, February 12). FDA Approves Roche\u2019s Evrysdi Tablet as First and only Tablet for Spinal Muscular Atrophy (SMA). Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2025-02-12."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: From phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2633105520973985","DOI":"10.1177\/2633105520973985","article-title":"The first orally deliverable small molecule for the treatment of spinal muscular atrophy","volume":"15","author":"Singh","year":"2020","journal-title":"Neurosci. Insights"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","article-title":"JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam","volume":"271","author":"Chiriboga","year":"2024","journal-title":"J. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mus.28329","article-title":"Transitioning from nusinersen to risdiplam for spinal muscular atrophy in clinical practice: A single-center experience","volume":"71","author":"Subramanian","year":"2025","journal-title":"Muscle Nerve"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"Oechsel","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_106","unstructured":"Cure SMA (2025, May 13). SMA Drug Pipeline. Available online: https:\/\/www.curesma.org\/sma-drug-pipeline\/."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Belan\u010di\u0107, A., Eustaquio, P., Gkrinia, E.M.M., Stevi\u0107, I., Javor, E., Lam, Y.W., Jankovi\u0107, S., and Vitezi\u0107, D. (2026). The evolving therapeutic landscape of spinal muscular atrophy\u2014A scoping review of investigational agents, emerging delivery technologies and strategic innovations. Br. J. Clin. Pharmacol., Epub ahead of print.","DOI":"10.1002\/bcp.70502"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1242\/dmm.029058","article-title":"Modelling amyotrophic lateral sclerosis: Progress and possibilities","volume":"10","author":"Robberecht","year":"2017","journal-title":"Dis. Model Mech."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"105156","DOI":"10.1016\/j.nbd.2020.105156","article-title":"The genetic architecture of ALS","volume":"147","author":"Shatunov","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature","volume":"41","author":"Logroscino","year":"2013","journal-title":"Neuroepidemiology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00415-019-09652-y","article-title":"Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"267","author":"Xu","year":"2020","journal-title":"J. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","article-title":"Incidence of amyotrophic lateral sclerosis in Europe","volume":"81","author":"Logroscino","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00415-025-12975-8","article-title":"Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): Current progress and future prospects","volume":"272","author":"Ruffo","year":"2025","journal-title":"J. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","article-title":"Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications","volume":"17","author":"Chia","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: Translating genetic discoveries into therapies","volume":"24","author":"Lopez","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat. Neurosci."},{"key":"ref_119","unstructured":"(2026, March 19). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/jnnp-2017-317611","article-title":"Comprehensive analysis of the mutation spectrum in 301 German ALS families","volume":"89","author":"Brenner","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1073\/pnas.80.18.5465","article-title":"Nucleotide sequence and expression of human chromosome 21-encoded superoxide dismutase mRNA","volume":"80","author":"Sherman","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"28087","DOI":"10.1074\/jbc.M704465200","article-title":"Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1","volume":"282","author":"Niwa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-9861(86)90526-6","article-title":"Biological effects of the superoxide radical","volume":"247","author":"Fridovich","year":"1986","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/brain\/awt097","article-title":"Is SOD1 loss of function involved in amyotrophic lateral sclerosis?","volume":"136","author":"Saccon","year":"2013","journal-title":"Brain"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a mouse model of ALS by in vivo base editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The deletion of mutant SOD1 via CRISPR\/Cas9\/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Duan","year":"2020","journal-title":"Gene Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2015.122","article-title":"Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates","volume":"27","author":"Borel","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_135","unstructured":"Arrowhead Pharmaceuticals (2025, June 05). Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS [Poster]. Available online: https:\/\/ir.arrowheadpharma.com\/static-files\/804aa94c-7323-4917-a04f-bd0812d2e2fb."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"S5.003","DOI":"10.1212\/WNL.0000000000212372","article-title":"RAG-17, a novel siRNA therapy for SOD1-ALS: Safety and preliminary efficacy from a first-in-human trial (S5.003)","volume":"104","author":"Ye","year":"2025","journal-title":"Neurology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12015-022-10489-8","article-title":"Amyotrophic lateral sclerosis, FUS and protein synthesis defects","volume":"19","author":"Assoni","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ene.12772","article-title":"Novel FUS mutations identified through molecular screening in a large cohort of familial and sporadic amyotrophic lateral sclerosis","volume":"22","author":"Tarlarini","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/mus.25061","article-title":"Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS\/TLS mutations in Japan","volume":"54","author":"Akiyama","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678421.2023.2272170","article-title":"FUS gene mutation in amyotrophic lateral sclerosis: A new case report and systematic review","volume":"25","author":"Xiao","year":"2024","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.15252\/embj.201593791","article-title":"Minor intron splicing is regulated by FUS and affected by ALS-associated FUS mutants","volume":"35","author":"Reber","year":"2016","journal-title":"EMBO J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nmd.2011.08.003","article-title":"P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis","volume":"22","author":"Conte","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","article-title":"Antisense oligonucleotide jacifusen for FUS-ALS: An investigator-initiated, multicentre, open-label case series","volume":"405","author":"Shneider","year":"2025","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Smeyers, J., Banchi, E.G., and Latouche, M. (2021). C9ORF72: What it is, what it does, and why it matters. Front. Cell. Neurosci., 15.","DOI":"10.3389\/fncel.2021.661447"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"Mackenzie","year":"2011","journal-title":"Neuron"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gde.2017.02.008","article-title":"Relationship between C9orf72 repeat size and clinical phenotype","volume":"44","author":"Cruts","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40478-019-0724-4","article-title":"C9orf72 intermediate expansions of 24\u201330 repeats are associated with ALS","volume":"7","author":"Iacoangeli","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.neurol.2024.03.008","article-title":"C9ORF72 hexanucleotide repeat expansion: From ALS and FTD to a broader pathogenic role?","volume":"180","author":"Sellier","year":"2024","journal-title":"Rev. Neurol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00401-020-02214-x","article-title":"C9orf72 loss-of-function: A trivial, stand-alone or additive mechanism in C9 ALS\/FTD?","volume":"140","author":"Braems","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.4490","article-title":"Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons","volume":"24","author":"Shi","year":"2018","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e101112","DOI":"10.15252\/embj.2018101112","article-title":"RNA toxicity in non-coding repeat expansion disorders","volume":"39","author":"Swinnen","year":"2020","journal-title":"EMBO J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","article-title":"Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS","volume":"77","author":"Ash","year":"2013","journal-title":"Neuron"},{"key":"ref_158","first-page":"E4530","article-title":"Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration","volume":"110","author":"Baughn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1474-4422(24)00216-3","article-title":"Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: A phase 1, randomised, double-blind, placebo-controlled, multiple ascending dose study","volume":"23","author":"Berg","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s13311-022-01285-w","article-title":"Approaches to gene modulation therapy for ALS","volume":"19","author":"Meijboom","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.13625","article-title":"Physiological functions and pathobiology of TDP-43 and FUS\/TLS proteins","volume":"138","author":"Ratti","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"a024554","DOI":"10.1101\/cshperspect.a024554","article-title":"Biology and pathobiology of TDP-43 and emergent therapeutic strategies","volume":"7","author":"Guo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1750-3639.2009.00284.x","article-title":"TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis","volume":"20","author":"Giordana","year":"2010","journal-title":"Brain Pathol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13024-020-00397-1","article-title":"The role of TDP-43 mislocalization in amyotrophic lateral sclerosis","volume":"15","author":"Suk","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/hmg\/ddp534","article-title":"Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo","volume":"19","author":"Kabashi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"102085","DOI":"10.1016\/j.arr.2023.102085","article-title":"TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia","volume":"92","author":"Babazadeh","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.omtn.2023.01.006","article-title":"Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS\/FTD mice","volume":"31","author":"Takeuchi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Amado, D.A., Robbins, A.B., Smith, A.R., Whiteman, K.R., Chillon Bosch, G., Chen, Y., Fuller, J.A., Izda, A., Nelson, S., and Dichter, A.I. (2024). AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS. bioRxiv.","DOI":"10.1101\/2024.01.31.578314"},{"key":"ref_172","unstructured":"Biogen and Ionis Pharmaceuticals (2024, May 16). Biogen and Ionis Announce Topline Phase 1\/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis. Available online: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-12-study-results."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","article-title":"Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration","volume":"22","author":"Melamed","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","article-title":"ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair","volume":"22","author":"Klim","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2013.11.007","article-title":"Dynamic regulation of SCG10 in regenerating axons after injury","volume":"252","author":"Shin","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.abq5622","article-title":"Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies","volume":"379","author":"Baughn","year":"2023","journal-title":"Science"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"P6","DOI":"10.1212\/WNL.0000000000205187","article-title":"QRL-201-01\u2014A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis (P6-11.010)","volume":"102","author":"Genge","year":"2024","journal-title":"Neurology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/d41573-025-00036-8","article-title":"Clinical development success rates for durable cell and gene therapies","volume":"24","author":"Phares","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41591-022-01889-x","article-title":"Early treatment is a lifeline for infants with SMA","volume":"28","author":"Sumner","year":"2022","journal-title":"Nat. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.crneur.2022.100064","article-title":"Visualizing advances in the future of primate neuroscience research","volume":"4","author":"Janssen","year":"2023","journal-title":"Curr. Res. Neurobiol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"eabj5633","DOI":"10.1126\/sciadv.abj5633","article-title":"Transplanted organoids empower human preclinical assessment of drug candidate for the clinic","volume":"8","author":"Fast","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Evangelisti, C., Ramadan, S., Orlacchio, A., and Panza, E. (2024). Experimental cell models for investigating neurodegenerative diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179747"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1002\/cpcb.51","article-title":"Transcription factor-mediated differentiation of human iPSCs into neurons","volume":"79","author":"Fernandopulle","year":"2018","journal-title":"Curr. Protoc. Cell Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2021.12.008","article-title":"Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation","volume":"29","author":"Giacomelli","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_186","unstructured":"(2025, May 27). Answer ALS. Available online: https:\/\/www.answerals.org."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","article-title":"iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders","volume":"29","author":"Okano","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"101659","DOI":"10.1016\/j.xcrm.2024.101659","article-title":"Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation","volume":"5","author":"Grass","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Faravelli, I., Rinchetti, P., Tambalo, M., Simutin, I., Mapelli, L., Mancinelli, S., Miotto, M., Rizzuti, M., D\u2019aNgelo, A., and Cordiglieri, C. (2025). Targeted antisense oligonucleotide treatment rescues developmental alterations in spinal muscular atrophy organoids. bioRxiv.","DOI":"10.1101\/2025.01.17.633436"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41593-021-00923-4","article-title":"Human ALS\/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology","volume":"24","author":"Wenger","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"113892","DOI":"10.1016\/j.celrep.2024.113892","article-title":"Neuromuscular organoids model spinal neuromuscular pathologies in C9orf72 amyotrophic lateral sclerosis","volume":"43","author":"Gao","year":"2024","journal-title":"Cell Rep."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s40478-024-01857-1","article-title":"Molecular pathology, developmental changes and synaptic dysfunction in (pre-)symptomatic human C9ORF72-ALS\/FTD cerebral organoids","volume":"12","author":"Jakobs","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_193","unstructured":"U.S. Food and Drug Administration (2025, October 25). Rare Diseases: Natural History Studies for Drug Development. Draft Guidance for Industry; FDA-2019-D-0481, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-natural-history-studies-drug-development."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e200213","DOI":"10.1212\/CPJ.0000000000200213","article-title":"Patient-reported impact of symptoms in spinal and bulbar muscular atrophy","volume":"13","author":"Alqahtani","year":"2023","journal-title":"Neurol. Clin. Pract."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ana.25681","article-title":"Clinical and molecular aspects of senataxin mutations in amyotrophic lateral sclerosis 4","volume":"87","author":"Grunseich","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_196","unstructured":"FDA-NIH Biomarker Working Group (2025, October 01). BEST (Biomarkers, EndpointS, and Other Tools) Resource, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/pdf\/Bookshelf_NBK326791.pdf."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1212\/WNL.0000000000008009","article-title":"Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity","volume":"93","author":"Klickovic","year":"2019","journal-title":"Neurology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e176383","DOI":"10.1172\/jci.insight.176383","article-title":"Protein biomarker signature in patients with spinal and bulbar muscular atrophy","volume":"9","author":"Tebbenkamp","year":"2024","journal-title":"JCI Insight"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4103\/NRR.NRR-D-24-00067","article-title":"Insights into spinal muscular atrophy from molecular biomarkers","volume":"20","author":"Xing","year":"2025","journal-title":"Neural Regen. Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"eadg6518","DOI":"10.1126\/science.adg6518","article-title":"Base editing rescue of spinal muscular atrophy in cells and in mice","volume":"380","author":"Arbab","year":"2023","journal-title":"Science"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-023-01132-z","article-title":"Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy","volume":"8","author":"Alves","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41467-024-55550-x","article-title":"Dual-targeting CRISPR-CasRx reduces C9orf72 ALS\/FTD sense and antisense repeat RNAs in vitro and in vivo","volume":"16","author":"Kempthorne","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41467-024-55548-5","article-title":"A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS\/FTD","volume":"16","author":"McCallister","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Bairqdar, A., Karitskaya, P.E., and Stepanov, G.A. (2024). Expanding Horizons of CRISPR\/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413321"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Wang, Z., Huang, J., and Yun, D. (2026). Current and Emerging Therapeutic Strategies for Amyotrophic Lateral Sclerosis: From Pharmacological Approaches to Gene and Stem Cell Therapies. Front. Neurol., 17.","DOI":"10.3389\/fneur.2026.1729302"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1002\/acn3.51887","article-title":"Therapeutic Targeting of ALS Pathways: Refocusing an Incomplete Picture","volume":"10","author":"Maragakis","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"107324","DOI":"10.1016\/j.nbd.2026.107324","article-title":"Skeletal Muscle in Spinal Muscular Atrophy: Critical Insights from Pathogenesis to Therapeutic Strategies","volume":"221","author":"Ottoboni","year":"2026","journal-title":"Neurobiol. Dis."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","article-title":"CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood\u2013Brain Barrier and Towards Specific Cellular Targeting","volume":"40","author":"Nozohouri","year":"2023","journal-title":"Pharm. Res."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/4\/419\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:06:47Z","timestamp":1775117207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/4\/419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":208,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["genes17040419"],"URL":"https:\/\/doi.org\/10.3390\/genes17040419","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}